Menstrual Cycle vs. Oral Contraceptives: Effects on Muscle Protein Metabolism After Resistance Exercise

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorUniversity of Toronto

About this trial

The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle.

Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons.

Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body.

The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.

Eligibility criteria

Qualifiers

Age: 18-40 years

BMI between 18.5-29.9 kg/m2 (non-obese)

Recreationally active (resistance train minimum twice a week)

Using monophasic or triphasic oral contraceptives for >1 year (for oral contraceptive users)

Disqualifiers

Mid-luteal progesterone levels <16umol

Chronic disease diagnosis (cardiovascular, thyroid, diabetes)

Current or recent remission of cancer

Regular use of non-steroidal anti-inflammatory drugs (NSAIDs; except low-dose aspirin), anticoagulants

Trial design

Treatments tested in this trial

  • Protein Beverage
  • Stable Isotope Tracer [D5]phenylalanine
  • Stable Isotope Tracer [13C]phenylalanine

Treatment groups

20 Participants
are divided into 4 treatment groups

Sponsors and collaborators